Apex Healthcare Berhad is a leading healthcare group headquartered in Malaysia, with operating subsidiaries in Malaysia and Singapore, and offices in Vietnam and Myanmar.
Founded in 1962 as a retail pharmacy in Melaka, our core expertise today is in the development, manufacturing, sales and marketing, distribution and wholesaling of pharmaceuticals and consumer healthcare products.
Apex Healthcare Berhad and all its subsidiaries and associates (collectively referred to as “Apex Healthcare” or “we” or “us” or “our”) respect and are committed to the protection of your personal data and your privacy. This Privacy Policy explains how we collect, store and handle your personal data in accordance with the Personal Data Protection Act 2010 (“PDPA”).
Please read this Privacy Policy to understand how we use the personal data that we may collect from you. By providing your personal data to us or using our website, you are consenting to the terms and conditions of this Privacy Policy and the collection, use, access, transfer, storage and processing of your personal data as described in this Privacy Policy. If you do not wish to give us this consent, kindly notify us in writing and do not use any of the electronic forms on our website. Failure to consent to the terms and conditions of this Privacy Policy will result in us being unable to process your application, request and/or provide you with the relevant product(s) or service(s).
We reserve the right to amend this Privacy Policy at any time without prior notice. We advise that you check this Privacy Policy on a regular basis at our website: www.apexhealthcare.com.my
1. DEFINING PERSONAL DATA
1.1 Type of Personal Data
Personal data means any information which relates directly or indirectly to you and which was collected or provided to Apex Healthcare for the purposes stated in Section 2 below. Your personal information may encompass your name, identity card/passport number, date of birth, age, gender, nationality and race, photograph, education, occupation, job title, employment details, membership of professional associations, contact details including address, e-mail address, phone number and facsimile number, marital status, financial and banking account details, security recordings and location tracking information, and may include in certain cases, sensitive personal information relating to your health and pertinent details concerning your family members and other personal information which may be supplied to us from time to time.
1.2 Source of Personal Data
We may collect personal data from you when you :
- communicate with us
- register interest and/or submit your application for employment with Apex Healthcare
- register interest and/or request for information of our product(s) and/or service(s)
- register or subscribe for any of our product(s) and/or service(s)
- respond to any marketing materials we send out or distribute
- commence a business relationship with us
- visit any of our premises
- visit or browse our websites
- lodge a complaint with us
- provide feedback to us
- participate in any of our surveys
- enter into or participate in any event, workshop or programme run/organised by us
- subscribe to Apex Healthcare Berhad shares in the Bursa Malaysia Securities Berhad Main Market
Other than personal information obtained from you directly (as detailed above), we may also obtain your personal information from third parties we deal with or are connected with you (previous employer(s), credit reference agencies or financial institutions), and from such other sources where you have given your consent for the disclosure of information relating to you, and/or where otherwise lawfully permitted.
1.3 Obligatory Personal Data
All information requested for in the relevant forms is obligatory to be provided by you unless stated otherwise. Should you fail to provide the obligatory information, we will not be able to process your application, request and/or provide you with the relevant product(s) or service(s).
2. HOW WE USE YOUR PERSONAL DATA
Your personal data will be/is being collected, used and/or processed by Apex Healthcare for amongst others, the following purposes:
- to verify your identity
- to enable us to discharge our contractual obligations
- to establish and better manage any business relationship we may have with you
- to engage in business transactions in respect of products and/or services to be offered and provided to you
- to assess and process your application/request for our product(s) and/or service(s)
- to keep in contact with you and provide you with any information you have requested or which may interest you
- for recruitment
- for training and development
- to be used for human resource-related purposes
- to notify you about benefits and changes to the features of our product(s) and/or service(s)
- to administer and manage the product(s) and/ or service(s) we provide you (including charging, billing, facilitating payments and collecting debts)
- to investigate and resolve any billing queries, complaints or other enquiries that you submit to us regarding our product(s) and/or service(s)
- to process any communication you send us (for example, dealing with any query, feedback or complaint)
- to assess and/or verify credit worthiness
- to conduct marketing activities (for example, market research)
- to facilitate your participation in any event, workshop or programme run/organised by us
- to develop, maintain and upgrade our business operating system and infrastructure for better efficiency
- to determine how we can improve our services to you
- to manage staff training and quality assurance
- to produce data, reports and statistics which shall be anonymised or aggregated in a manner that does not identify you as an individual
- to investigate, respond to, or defend claims made against, or involving Apex Healthcare
- to detect and prevent fraudulent activity
- to maintain records required for security, claims or other legal purposes
- to comply with legal and regulatory requirements and obligations
- for any other purposes that is required or permitted by any law, regulations, guidelines and/or relevant regulatory authorities
3. DISCLOSURE OF PERSONAL DATA
Apex Healthcare will keep your personal data confidential but you hereby consent and authorise Apex Healthcare to disclose your personal data to relevant third parties (in and/or outside Malaysia) including:
- Third parties appointed by us to provide services to us or on our behalf (for example auditors, lawyers, company secretary, consultants, contractors, professional advisors, service providers, printing companies, contractors, business partners, conference/training/event organiser, other advisors, travel agencies and insurance companies);
- Any related, affiliated and subsidiaries or associated companies of Apex Healthcare;
- Property management/utility/security companies for management of property purchased; and
- Relevant government agencies, statutory authorities, local council and industry regulators.
4. STORAGE AND RETENTION OF PERSONAL DATA
Your personal data will be stored either in hard copies in our premises or stored in servers located in Malaysia and will either be operated by us or our appointed service providers, consultants or advisors. Apex Healthcare does not rent or sell your personal data to third parties. Apex Healthcare will retain your personal data for the period necessary to fulfill the legal requirements of data retention as stipulated by the respective laws of Malaysia or to protect our interests.
5. PERSONAL DATA INTEGRITY AND SECURITY
We will take reasonable steps to make sure that the personal data we collect, use or disclose is accurate, complete, not misleading and up-todate. We shall keep and process your data in a secure manner. We endeavour, where practicable, to implement the appropriate administrative and security safeguards and procedures in accordance with the applicable laws and regulations to prevent the unauthorised or unlawful processing of your personal data and the accidental loss or destruction of, or damage to, your personal data.
In the event that transfer of your personal data outside of Malaysia is rendered necessary for the performance of the services required of us, the transfer of data will be done in accordance with the requirements of the PDPA and you are deemed to have consented to the said data transfer.
6. ACCESS AND CORRECTION TO YOUR PERSONAL DATA
You have the qualified right to access and correct your personal data held by us and in this respect, you may:
- check if we hold or use your personal data and request access to your personal data;
- request for correction of any of your personal information which is inaccurate, incomplete or not up-todate;
- request for explanation on the policies and procedures in respect of your personal data provided to Apex Healthcare;
- request Apex Healthcare to stop processing your personal data for marketing purposes;
- request Apex Healthcare to limit the process of your personal data, including personal data limiting to the persons who may be identified
from your personal data; and - inform Apex Healthcare on your withdrawal (in full or in part) of your consent given previously to Apex Healthcare subject to any applicable
restrictions, contractual conditions and a reasonable duration of time for the withdrawal of consent to be effected.
You may notify us in writing if you do not wish to receive any marketing materials from us and we shall immediately remove you from our marketing contact list.
We recommend that requests for access to your personal data be made in writing. We may also require you to provide us with additional information reasonably required to process your request.
Please note that under the PDPA, we have the right to refuse your requests to access or correct your personal data for certain reasons permitted under the PDPA. We have the right to also charge an administrative fee for responding to your requests.
7. YOUR OBLIGATIONS REGARDING YOUR PERSONAL DATA
You are responsible for informing us about changes to your personal data and for ensuring that such information is accurate, up-to-date and complete.
In the event you may need to provide us with personal data relating to third parties (for example about your spouse or children or where you are the designated person in charge for dealing with us or if you are acquiring and are responsible for a product and/or service that they will use), you confirm that you have (i) obtained their consent or otherwise entitled to provide their personal data to us and for us to use accordingly, and (ii) informed them to read this Privacy Policy at our website.
If you are using our website, you must remember to exit the browser window after use to prevent any unauthorised access to your personal data.
8. CONTACT INFORMATION
If you have any queries, please contact us at +603-56376888 from Monday to Friday (8.15am – 5pm, excluding public holidays) or e-mail us at enquiry@apexpharmacy.com.my
Apex Healthcare Berhad dan semua anak-anak syarikat dan syarikat bersekutu (dirujuk secara kolektif sebagai “Apex Healthcare” atau “kami”) hormat dan komited untuk melindungi maklumat peribadi dan privasi anda. Polisi Privasi ini menjelaskan bagaimana kami mengumpul, menyimpan dan mengendali maklumat peribadi anda selaras dengan Akta Perlindungan Data Peribadi 2010 (‘APDP’).
Sila baca Polisi Privasi ini untuk memahami bagaimana kami menggunakan maklumat peribadi yang mungkin kami kumpulkan daripada anda. Dengan memberi maklumat peribadi anda kepada kami atau mengunakan laman web kami, anda telah bersetuju dengan terma dan syarat Polisi Privasi ini dan pengumpulan, penggunaan, pengaksesan, pemindahan, penyimpanan dan pemprosesan maklumat peribadi anda seperti yang diterangkan dalam Polisi Privasi ini. Sekiranya anda tidak ingin memberi kebenaran ini kepada kami, sila maklumkan kepada kami secara bertulis dan elak daripada menggunakan mana-mana borang elektronik di laman web kami. Kegagalan untuk bersetuju dengan terma dan syarat-syarat Polisi Privasi ini akan mengakibatkan pihak kami tidak dapat memproses permohonan anda, permintaan dan/atau membekalkan kepada anda produk atau perkhidmatan yang berkaitan.
Kami berhak untuk meminda Polisi Privasi ini dari masa ke semasa tanpa memberi notis terlebih dahulu. Sila semak laman web kami untuk maklumat mengenai Polisi Privasi yang terkini www.apexhealthcare.com.my
1. DEFINISI MAKLUMAT PERIBADI
1.1 Jenis Maklumat Peribadi
Maklumat peribadi merujuk kepada apa-apa maklumat yang berkaitan secara langsung atau tidak langsung kepada anda yang dikumpulkan atau diberikan kepada Apex Healthcare bagi kegunaan yang diterangkan dalan Bahagian 2 di bawah. Maklumat peribadi anda mungkin merangkumi nama, nombor kad pengenalan/nombor pasport, tarikh lahir, umur, jantina, kewarganegaraan dan bangsa, gambar, pendidikan, pekerjaan, jawatan, maklumat majikan, keahlian persatuan profesional, butiran perhubungan termasuk alamat rumah, alamat emel, nombor telefon dan nombor fax, status perkahwinan, butiran kewangan dan akaun perbankan, rekod keselamatan dan maklumat mengesan lokasi, dan mungkin merangkumi kes-kes tertentu, maklumat peribadi yang sensitif yang berkaitan dengan maklumat kesihatan dan butiran berkaitan ahli keluarga anda dan maklumat peribadi lain yang mungkin dibekalkan kepada pihak kami dari semasa ke semasa.
1.2 Sumber Maklumat Peribadi
Kami akan mengumpulkan maklumat peribadi daripada anda apabila anda:
- berkomunikasi dengan kami
- mendaftar minat dan/atau mengemukakan permohonan pekerjaan dengan Apex Healthcare
- mendaftar minat dan/atau memohon maklumat mengenai produk dan/atau perkhidmatan kami
- mendaftar untuk atau melanggan produk dan/atau perkhidmatan kami
- menjawab apa-apa bahan pemasaran yang kami hantar keluar
- memulakan hubungan perniagaan dengan kami
- mengunjungi mana-mana pejabat kami
- melawat atau melayari laman-laman web kami
- membuat aduan kepada kami
- memberi maklumbalas kepada kami
- menyertai kaji selidik kami
- memasuki atau menyertai mana mana acara, bengkel atau program yang dianjurkan/dikendalikan oleh kami
- membeli saham Apex Healthcare Berhad di Bursa Malaysia Papan Pertama
Selain daripada maklumat peribadi yang diperolehi secara terus daripada anda (seperti yang dinyatakan di atas), kami juga mungkin memperolehi maklumat peribadi anda daripada pihak-pihak ketiga yang berurusan dengan kami atau yang berkaitan dengan anda (majikan terdahulu, agensi rujukan kredit atau institusi kewangan), dan daripada sumber-sumber lain yang telah anda memberi kebenaran untuk pendedahan maklumat berkaitan dengan anda, dan/atau di mana dibenarkan dari segi undang-undang.
1.3 Maklumat Peribadi Wajib
Semua maklumat yang diminta di dalam borang-borang yang berkaitan adalah wajib untuk anda bekalkan melainkan dinyatakan sebaliknya. Sekiranya anda gagal untuk membekalkan maklumat wajib, pihak kami tidak dapat memproses permohonan anda, permintaan dan/atau membekal produk atau perkhidmatan yang berkaitan kepada anda.
2. BAGAIMANA KAMI MENGGUNAKAN MAKLUMAT PERIBADI ANDA
Maklumat peribadi anda dikumpulkan, digunakan dan/atau diproses oleh Apex Healthcare untuk satu atau lebih tujuan-tujuan berikut :
- untuk mengesahkan identiti anda
- untuk membolehkan kami menunaikan kewajipan kontrak kami
- untuk menjalin dan menguruskan dengan lebih baik apa-apa perhubungan perniagaan yang kami mungkin ada dengan anda
- untuk memasuki transaksi perniagaan berkenaan dengan produk dan/atau perkhidmatan yang hendak ditawarkan dan dibekalkan kepada anda
- untuk mempertimbangkan dan memproses permohonan/permintaan anda untuk produk dan/atau perkhidmatan kami
- untuk sentiasa berhubung dengan anda dan menyediakan anda dengan maklumat yang diminta atau yang mungkin menarik minat anda
- untuk pengambilan pekerja
- untuk latihan dan pembangunan
- untuk tujuan yang berkaitan dengan sumber manusia
- untuk memaklumkan anda tentang manfaat dan perubahan kepada ciri-ciri produk dan/atau perkhidmatan kami
- untuk mengendali dan mengurus produk dan/atau perkhidmatan yang kami sediakan untuk anda (termasuk pengenaan bayaran, pengebilan, kemudahan pembayaran dan pengutipan hutang)
- untuk menyiasat dan menyelesaikan apa-apa pertanyaan mengenai bil, aduan atau pertanyaan-pertanyaan lain yang anda berikan kepada kami mengenai produk dan/atau perkhidmatan kami
- untuk memproses komunikasi yang anda hantar kepada kami (contohnya, menjawab pertanyaan dan menangani apa-apa aduan dan maklum balas)
- untuk menilai dan/atau mengesahkan kelayakan kredit
- untuk menjalankan aktiviti pemasaran (contohnya, kajian pasaran)
- untuk memudahkan penyertaan anda dalam mana-mana acara, bengkel atau program yang dianjurkan/dikendalikan oleh kami
- untuk membina, mengekalkan dan menaik taraf sistem operasi perniagaan dan infrastruktur kami untuk mencapai kecekapan yang lebih baik
- untuk memastikan cara kami dapat meningkatkan perkhidmatan kami kepada anda
- untuk menguruskan latihan kakitangan dan jaminan kualiti
- untuk menghasilkan data, laporan dan statistik yang akan dianonim atau diagregatkan dengan cara yang tidak mengenalpasti anda sebagai individu
- untuk menyiasat, membalas atau membela tuntutan yang dibuat terhadap atau melibatkan Apex Healthcare
- untuk mengesan dan mencegah aktiviti penipuan
- untuk menyenggara rekod-rekod untuk tujuan keselamatan, tuntutan atau tujuan undang-undang lain
- untuk mematuhi keperluan undang-undang dan pengawalseliaan
- untuk apa-apa tujuan lain yang diperlukan atau dibenarkan oleh apa-apa undang-undang, peraturan, garis panduan dan/atau pihak-pihak pengawalselia berkuasa yang berkenaan.
3. PENDEDAHAN MAKLUMAT PERIBADI ANDA
Apex Healthcare akan menyimpan maklumat peribadi anda secara rahsia dan anda bersetuju dan memberi kuasa kepada Apex Healthcare untuk mendedahkan maklumat peribadi anda kepada pihak-pihak ketiga yang berkaitan (di dalam dan/atau di luar Malaysia) termasuk:
- pihak-pihak ketiga yang dilantik oleh kami untuk membekalkan perkhidmatan kepada kami atau bagi pihak kami (contohnya, juruaudit, peguam, setiausaha syarikat, perunding, kontraktor, penasihat-penasihat profesional, pembekal perkhidmatan, syarikat-syarikat percetakan, kontraktor, rakan niaga, penganjur persidangan/latihan/acara, penasihat-penasihat lain, agensi-agensi pelancongan dan syarikat-syarikat insurans);
- syarikat-syarikat yang berkaitan, anak syarikat atau syarikat bersekutu Apex Healthcare;
- syarikat pengurusan hartanah/utiliti/keselamatan untuk pengurusan hartanah yang dibeli; dan
- agensi-agensi kerajaan, badan berkanun, majlis tempatan dan pengawalselia industri yang berkaitan.
4. PENYIMPANAN DAN PENGEKALAN MAKLUMAT PERIBADI
Maklumat peribadi anda akan disimpan sama ada dalam bentuk cetakan di premis kami di Malaysia atau disimpan di dalam server yang dikendalikan oleh kami atau pembekal server, perunding atau penasihat yang dilantik oleh kami di Malaysia. Apex Healthcare tidak menyewa atau menjual maklumat peribadi anda kepada pihak-pihak ketiga. Apex Healthcare akan mengekalkan maklumat peribadi anda untuk tempoh yang diperlukan demi memenuhi keperluan undang-undang pengekalan data seperti yang ditetapkan oleh undang-undang Malaysia yang tertentu atau melindungi kepentingan kami.
5. INTEGRITI DAN KESELAMATAN MAKLUMAT PERIBADI
Kami akan mengambil langkah-langkah yang munasabah untuk memastikan bahawa maklumat peribadi yang kami kumpulkan, gunakan atau dedahkan adalah tepat, lengkap, tidak mengelirukan dan terkini. Kami akan menyimpan dan memproses maklumat anda dengan selamat. Sekiranya cara yang digunakan adalah praktik, kami akan berusaha untuk melaksanakan pentadbiran dan keselamatan perlindungan serta prosedur yang sesuai selaras dengan undang-undang dan peraturan, untuk menghalang pemprosesan maklumat peribadi anda yang tidak dibenarkan atau salah di sisi undang-undang serta mencegah kehilangan maklumat peribadi anda secara tidak sengaja atau pemusnahan, atau kerosakan kepada maklumat peribadi anda.
Sekiranya pemindahan maklumat anda keluar daripada Malaysia diperlukan bagi pelaksanaan perkhidmatan yang diperlukan daripada kami, pemindahan maklumat akan dilakukan mengikut keperluan APDP dan anda dianggap telah bersetuju dengan pemindahan maklumat tersebut.
6. PENGAKSESAN DAN PEMBETULAN MAKLUMAT PERIBADI ANDA
Anda layak untuk memiliki hak mengakses dan membuat sebarang pembetulan maklumat peribadi anda yang dipegang oleh kami dan berkenaan hal ini, anda boleh:
- memeriksa sekiranya kami memegang atau menggunakan maklumat peribadi anda dan meminta akses kepada maklumat peribadi anda;
- meminta pembetulan maklumat peribadi anda yang tidak tepat, tidak lengkap atau bukan terkini;
- meminta penjelasan mengenai polisi-polisi dan prosedur berkenaan dengan maklumat peribadi anda yang diberikan kepada Apex Healthcare;
- meminta Apex Healthcare untuk menghentikan pemprosesan maklumat peribadi anda untuk tujuan pemasaran;
- meminta Apex Healthcare untuk menghadkan proses maklumat peribadi anda, termasuk maklumat yang boleh dikenalpasti daripada maklumat peribadi anda; dan
- memaklumkan Apex Healthcare tentang keengganan anda (sepenuhnya atau sebahagian) memberi kebenaran yang telah diberikan sebelum ini kepada Apex Healthcare tertakluk kepada apa-apa sekatan yang ada, syarat kontrak dan tempoh masa yang munasabah untuk keengganan itu diperlaksanakan.
Anda boleh memberitahu kami secara bertulis sekiranya anda tidak ingin menerima apa-apa bahan pemasaran daripada kami dan kami akan membatalkan nama anda daripada senarai hubungan pemasaran kami.
Kami mengesyorkan bahawa permintaan untuk akses kepada data peribadi anda dibuat secara bertulis. Kami juga mungkin memerlukan anda untuk memberi kami maklumat tambahan yang dikehendaki secara munasabah bagi memproses permintaan anda.
Sila ambil perhatian bahawa di bawah APDP, kami berhak untuk menolak permintaan anda untuk mengakses atau membetulkan maklumat peribadi anda atas sebab-sebab tertentu yang dibenarkan di bawah APDP. Kami mempunyai hak untuk mengenakan caj pentadbiran untuk menangani permintaan anda.
7. KEWAJIPAN ANDA TERHADAP MAKLUMAT PERIBADI ANDA
Anda bertanggungjawab untuk memaklumkan kami mengenai perubahan maklumat peribadi anda dan memastikan bahawa maklumat tersebut adalah tepat, terkini dan lengkap.
Jika anda perlu untuk memberi kami maklumat peribadi berkaitan dengan pihak-pihak ketiga (contohnya mengenai suami atau isteri atau anak-anak anda atau di mana anda merupakan orang yang dilantik untuk berurusan dengan kami atau jika anda sedang memperolehi dan bertanggungjawab untuk produk dan/atau perkhidmatan yang mereka akan gunakan), anda mengesahkan yang anda telah (i) mendapatkan kebenaran mereka atau sebaliknya anda berhak memberi maklumat peribadi mereka kepada kami dan untuk kami menggunakan maklumat peribadi tersebut dengan sewajarnya, dan (ii) memberitahu mereka untuk membaca Polisi Privasi ini di laman web kami.
Sekiranya anda menggunakan laman web kami, anda diingatkan untuk menutup tetingkap pelayar selepas pengunaan bagi mengelakkan sebarang akses yang tidak dibenarkan kepada maklumat peribadi anda.
8. MAKLUMAT HUBUNGAN
Sekiranya anda mempunyai sebarang pertanyaan, sila hubungi kami di talian +603-56376888 dari Isnin hingga Jumaat (8.15pagi – 5.00petang, cuti am dikecualikan) atau emel kami di enquiry@apexpharmacy.com.my
2. Board Composition
2.1 The Board shall be composed of a combination of Directors with a mix of skills appropriate to providing the necessary breadth and depth of knowledge and experience to serve the Company’s best interests.
2.2 While boardroom diversity remains a main criterion for Board composition, no regard shall be paid to gender, race or religion when considering specific candidates for appointment to the Board. Suitability of qualifications, experience and synergy with the overall composition of the Board are factors which the Company values and will take into account.
2.3 The size of the Board shall be determined by the needs of the Company. Nevertheless, Board composition shall always be in full compliance with all current and applicable laws and regulations.
2.4 The Board shall establish and maintain a Nomination Committee to regularly review the number, mix and effectiveness of Directors on the Board so as to determine whether the Board remains appropriate and effective, subject to any applicable regulatory constraints.
3. Role of Board
3.1 The Board’s role is to represent and serve the interests of shareholders by overseeing and appraising the Company’s strategies and policies and monitoring management’s implementation of them. The Board’s principal objective is to maintain and increase shareholder value while ensuring that the Group’s overall activities are properly managed.
3.2 The Board is answerable to shareholders generally, and specifically to General Meetings of shareholders.
3.3 The list below are matters specifically reserved for the Board’s decision:
i. Any substantial change in existing businesses and/or the entry and diversification into new and unrelated businesses by the Company and Group.
ii. The change in name of the Company or any of its subsidiary companies.
iii. The change in the share capital of the Company or any of its subsidiary companies.
iv. The acquisition or sale of intangible assets such as trademarks, intellectual property or licenses except in the ordinary course of business.
v. The licensing out of the Group’s trademarks or intellectual property except in the ordinary course of business.
vi. The entry into related party transactions with a value exceeding 0.25% of any of the percentage ratios as defined in Chapter 10 of Bursa Malaysia Securities Berhad’s Main Market Listing Requirements (“MMLR”) or is RM500,000 or more.
vii. The acquisition of any properties, quoted or unquoted securities.
viii. The appointment and changes of the Company’s cheque signatories and their associated limits of authority.
ix. The appointment and changes of the Company’s corporate representatives.
x. The Group’s annual operating and capital expenditure budget and business strategies associated therewith.
xi. The Company’s material communications to the public and/or shareholders, including Press Releases, Announcements, Annual Reports, Letters, Circulars, and the Group’s policies and commitments on anti-corruption.
xii. The calling of General Meetings of the Company except where such meetings have been properly called by shareholders independently of the Board as provided for in the Company’s Constitution.
xiii. The recommendation of dividend payments for shareholders’ approval and the dates for closure of books.
xiv. The entry into or termination of any contract that is likely to have a material impact on the financial performance of the Group.
xv. Changes to the composition of the Board of Directors and Board Committees.
xvi. Changes to the Terms of Reference of Board Committees.
xvii. Changes to the corporate structure of the Group involving movement in shareholding structures including the incorporation and/or acquisition of new subsidiary or associated companies, divestment of subsidiaries or associated companies and entry into joint ventures.
xviii. Appointment and resignation/termination of the Chief Executive Officer and Chief Financial Officer.
xix. Appointment and resignation/termination of advisors such as merchant bankers, external auditors, internal auditors and company secretaries by the Group.
xx. The procurement of banking facilities for the Group, the charging of any of the Company’s or its subsidiary companies’ assets and the giving of corporate guarantees by the Company.
xxi. Any matter for which Board approval is required by law as specified in the MMLR, guidelines of the Securities Commission, the Companies Act 2016, the Malaysian Code on Corporate Governance, Malaysian Anti-Corruption Commission Act 2009 (Act 694) and any other relevant authority.
xxii. The Group’s general stance against corrupt practices in relation to its business activities.
xxiii. The Group’s anti-corruption compliances and the monitoring of anti-compliance initiatives throughout AHB Group.
xxiv. Succession planning of members of the Board.
xxv. Any matter for which Board approval is required under the Company’s Constitution.
xxvi. Any other matter that the Board may include in this schedule from time to time.
3.4 The Board shall meet at least 4 times a year, and Directors will allocate sufficient time to perform their duties effectively.
4. Role of Directors
4.1 Directors will act at all times with honesty and integrity, and will observe high standards of ethical behaviour.
4.2 Directors should not place their personal interests over the Company’s interests.
4.3 In addition to attending formal Board and Board committee meetings, the Directors may be requested to undertake other reasonable duties including membership of ad hoc committees, attending management meetings, and participation in special projects.
4.4 Directors should avail themselves of programmes and continuing education, training or development programs arranged for them by the Company.
4.5 The Board, its committees, and Directors individually, may take independent professional advice, as necessary, at the Company’s expense, subject to prior consultation with the Chairman. Advice so received will be made available to all Directors if it is appropriate to so.
4.6 The Board considers Directors to be Independent where they take no part in management and are free of business or other relationships that could materially interfere with or could reasonably be perceived to materially influence the exercise of their unfettered and independent judgment of what is in the best interests of the Company. In the case where an Independent Director retires from the Board and is subsequently considered again for appointment as an Independent Director, the candidate shall be subject to a two year cooling-off period after which he may be deemed independent for purposes of serving on the Board or any Board Committee. At minimum, Independent Directors must satisfy the definition of independence promulgated in the MMLR.
4.7 The Board shall spell out expectations on the time commitment expected of Directors.
4.8 Acceptance of new directorships should be disclosed to the Board in a timely fashion and should not result in a conflict with the discharge of Directors’ duties to the Company. Directors are not permitted to hold more than five (5) directorships of listed companies in Malaysia, including that of the Company itself.
5. Role of Chairman
5.1 The Board shall appoint one of its members to be Chairman.
5.2 The Chairman will:
i. Provide leadership for the Board so that the Board can perform its responsibilities effectively;
ii. Chair general meetings of shareholders;
iii. Represent the Board to shareholders and communicates the Board’s position and ensures appropriate steps are taken to provide effective communication with shareholders and other stakeholders;
iv. Lead the Board and facilitates and encourages constructive discussion and debate during Board meetings;
v. Promote constructive and respectful relations and manages the interface between the Board and management;
vi. Determine, in consultation with management, the agenda for the Board’s deliberations;
vii. Ensure that the Board and its committees are fully supplied with the information and resources necessary to discharge its duties effectively; and
viii. Lead the Board in the adoption and implementation of good corporate governance practices in the Company.
5.3 The Chairman of the Board shall not be a member of the Audit Committee, Nomination Committee or Remuneration Committee.
6. Role of Senior Independent Director (“SID”)
6.1 The Board may appoint one of its Independent Directors to be the SID.
6.2 The SID will :
i. Assume the role of Chairman when the Chairman is unable to act in that capacity as a result of his lack of independence in the spirit of good corporate governance practices;
ii. Provide a sounding board for the Chairman to discuss confidential issues related to governance, Board performance and effectiveness, and concerns raised by Directors, shareholders and other stakeholders;
iii. Provide a point of contact for shareholders and other stakeholders to raise issues and concerns which they feel have not been resolved through normal channels; and
iv. Serve as an intermediary for other Directors when necessary.
7. Role of Chief Executive Officer (“CEO”)
7.1 The day-to-day management of operations of the Company and Group is the responsibility of the CEO who reports to the Board on key management issues, which include:
i. Developing and implementing corporate strategies and making recommendations to the Board on significant corporate strategic initiatives;
ii. Submission of an annual budget for consideration and approval by the Board;
iii. Maintaining effective risk management and compliance management frameworks;
iv. Appointing and determining the terms of appointment of Senior Management, developing and maintaining succession plans, and monitoring the performance of key executives;
v. Informing the Board of material continuous disclosure;
vi. Ensuring that the Company and Group remain in compliance with all applicable and relevant regulations and laws; and
vii. Managing operations in accordance with any applicable standards for social, ethical and environmental practices.
8. Board Committees
8.1 The Board shall establish Board committees as appropriate and necessary to assist it in matters that require particular review. The ultimate responsibility for decisions and recommendations taken by the Board committees rests with the Board as a whole. The following are permanent Board committees:
i. Audit Committee
ii. Nomination Committee
iii. Remuneration Committee
iv. Risk and Sustainability Committee
8.2 The duties of these committees are specified in their own Terms of Reference which are reviewed from time to time. The Terms of Reference and composition of the committees are specified in the appendices to this Board Charter.
8.3 The Terms of Reference of the Audit Committee are specified in Appendix A, the Remuneration Committee in Appendix B, the Nomination Committee in Appendix C and the Risk and Sustainability Committee in Appendix D.
8.4 The Board may also delegate specific functions to ad hoc committees as and when need dictates.
Appendix A
Terms of Reference of the Audit Committee
1. Constitution
The Board has established a Committee of the Board to be known as the Audit Committee (hereinafter known as the “AC”) with authority and duties as specified in these Terms of Reference.
2. Membership of the Committee
2.1 The AC shall be appointed by the Board from amongst the Directors of the Company and shall consist of at least 3 members, comprising exclusively of Non-Executive Directors, a majority of whom shall be Independent Non-Executive Directors. A quorum requires the majority of members present to be Independent Directors.
2.2 At least one member of the AC must be a member of the Malaysian Institute of Accountants. If there is none, one member must either have at least 3 years’ working experience and (a) have passed the examinations specified in Part 1 of the First Schedule of the Accountants Act, 1967, or (b) be a member of one of the associations of accountants specified in Part II of the 1st Schedule of the Accountants Act 1967; or have the following qualifications:-
i. a degree/masters/doctorate in accounting or finance and at least 3 years’ post qualification experience in accounting or finance; or
ii. at least 7 years’ experience being a chief financial officer of a corporation or having a function of being primarily responsible for the management of the financial affairs of a corporation.
2.3 No alternate Director shall be appointed as a member of the AC.
2.4 The Board of Directors must via the Nomination Committee review the composition, term of office and performance of the AC and its members annually to determine whether the AC and its members have carried out their duties in accordance with its Terms of Reference.
2.5 The members of the AC shall elect a Chairman from among their number who shall be an Independent Non-Executive Director. The Chairman of the AC shall not be the Chairman of the Board.
2.6 If a member of the AC resigns, dies or for any other reason ceases to be a member with the result that the number of members is reduced below 3, the Board of Directors shall, within 3 months of that event, appoint such number of new members as may be required to make up the minimum number of 3 members.
2.7 The Company Secretary shall be the Secretary of the AC.
2.8 No former partner of the external audit firm of the Company shall be appointed as a member of the AC unless a cooling-off period of at least three years have lapsed.
3. Rights of the Audit Committee
3.1 The AC shall, wherever necessary and reasonable for the performance of its duties, in accordance with procedures stipulated by the Board of Directors and at the cost of the Company;
i. have authority to investigate any matter within its Terms of Reference;
ii. have the resources that are required to perform its duties;
iii. have full and unrestricted access to any information pertaining to the Company and the Group;
iv. have direct communication channels with the External Auditors and person(s) carrying out the internal audit function or activity;
v. be able to obtain independent professional or other advice and to invite outsiders to attend AC meetings where necessary;
vi. be able to convene meetings with the External Auditors and Internal Auditors, without the presence of any employees, at least twice a year and whenever deemed necessary;
vii. have authority to assign and adequately resource a function (which may be external to the organisation) to be responsible for the Group’s anti-corruption framework as well as anti-corruption compliance matters, including provision of advice and guidance to personnel and business associates in relation to the corruption programme;
viii. have authority to direct efforts to improve upon the effectiveness of its corruption risks management framework; and
ix. have authority to investigate matter related to anti-corruption and other matters within its terms of reference.
3.2 The AC shall take into cognizance in its deliberations the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Malaysian Code on Corporate Governance, Malaysian Anti-Corruption Commission Act 2009 (Act 694) and any other pertinent regulations and laws, as well as revisions which may come into force thereafter.
3.3 Where the AC is of the view that a matter reported by it to the Board has not been satisfactorily resolved resulting in a breach of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the AC shall report such matter to Bursa Malaysia Securities Berhad.
4. Duties and Functions of the Audit Committee
4.1 The AC shall review the following and report the same to the Board of Directors:-
i. with the External Auditors, the nature and scope of the audit before commencement;
ii. with the internal audit function or external consultants, their evaluation of the system of risk management, including business risk management, corruption risk management and internal controls assisted and supported by the Risk and Sustainability Committee;
iii. with the External Auditors, the audit reports, management letters and management response;
iv. the assistance given by the Company’s employees and officers to the External Auditors;
v. the adequacy of the scope, competency and resources of the internal audit function and that it has the necessary authority to carry out its work;
vi. the internal audit plan, processes, the results of the internal audit assessments, investigation undertaken and whether or not appropriate action is taken on the recommendations;
vii. any appraisal or assessment of the performance of members of the internal audit function;
viii. the financial reports at the end of each quarter and year end, prior to approval by the Board of Directors, focusing particularly on:-
- changes in or implementation of major accounting policy changes;
- significant matters highlighted including financial reporting issues, significant judgements made by management, significant and unusual events or transactions and how these matters are being addressed; and
- compliance with accounting standards and other legal requirements;
ix. any related party transaction and conflict of interest situation that arose, persist or may arise within the Company or Group including any transaction, procedure or course of conduct that raises questions of management integrity; and the measures taken to resolve, eliminate, or mitigate such conflicts;
x. any letter of resignation from the External Auditors;
xi. whether there is reason (supported by grounds) to believe that the External Auditors is not suitable for re-appointment;
xii. the Group’s exposure to corruption risk and to make recommendations on anti-corruption management and corruption risk mitigation;
xiii. the design and effectiveness of the Group’s anti-corruption framework;
xiv. the implementation of the Group’s anti-corruption monitoring program in relation to the Group’s exposure to corruption risks;
xv. the implementation of the Group anti-corruption compliance programmes and to review its effectiveness thereof;
xvi. the resources and effectiveness of the Anti-Corruption Function of the Group and to determine the adequacy of corruption risk reporting;
xvii. the knowledge sharing on anti-corruption initiatives throughout the Group;
xviii. the awareness of employees, contractors, agents and suppliers regarding the Group’s anti-corruption policies and stand;
xix. the Company’s website contains information that is up-to-date and coherently reflective of the Group’s anti-corruption approaches, policies, procedures, systems and activities, which is updated on a periodic basis;
xx. any corruption related matters within its terms of reference (and shall have the resources which it needs to do so) and to seek any information it requires from any officers or employee of the Group and such officers or employees shall respond to such enquiries on a timely manner and to co-operate with the Committee;
xxi. engagement of independent professional advice (including legal advice), where necessary, and to secure the attendance of outsiders with relevant expertise or experience as it considers necessary to assist in any anti-corruption matters; and
xxii. Statement on Risk Management and Internal Control with support by the Risk and Sustainability Committee for approval by the Board for inclusion in the Annual Report of the Company.
4.2 The AC shall review any matters concerning the appointment/re-appointment and dismissal of both the Internal and External Auditors, their audit fees and render its recommendations accordingly to the Board of Directors. In considering the appointment/re-appointment and dismissal of the External Auditors, to consider among others:-
i . the adequacy of the experience and resources of the accounting firm;
ii. the persons assigned to the audit;
iii. the accounting firm’s audit engagements;
iv. the size and complexity of the listed issuer’s group being audited; and
v. the number and experience of supervisory and professional staff assigned to the particular audit.
4.3 The AC shall evaluate and assess the performance of External Auditors, in terms of the following:-
i. the suitability, objectivity and independence of the External Auditors;
ii. the External Auditors’ ability to meet deadlines in providing services and responding to issues in a timely manner as contemplated in the external audit plan;
iii. the nature of the non-audit services provided by the External Auditors and fees paid for such services relative to the audit fee; and
iv. whether there are safeguards in place to ensure that there is no threat to the objectivity and independence of the audit arising from the provision of non-audit services or tenure of the External Auditors.
4.4 The AC shall discuss the contracts and nature for the provision of non-audit services which can be entered into by the Group with the External Auditors or its affiliates and procedures that must be followed. The contracts to be entered into shall not include:-
i. Management consulting;
ii. Strategic decision;
iii. Internal audit; and
iv. Policy and standard operating procedures documentation.
In the event that the non-audit fees paid to the Company’s External Auditors, or a firm or corporation affiliated to the External Auditors’ firm are significant (e.g. constitute 50% of the total amount of audit fees paid to the Company’s External Auditors) the Company is required to state the details on the nature of non-audit services rendered in the Report of the Audit Committee.
The AC shall approve any appointment or termination of senior staff members of the internal audit function; take cognizance of resignations of internal audit staff and provide resigning staff member an opportunity to submit reasons for resigning or if the internal audit function is outsourced, then the AC shall evaluate and assess the performance of outsourced Internal Auditors, including their independence, competency, experience and resources to carry out the function effectively. The AC shall consider the major findings of internal investigations and management’s response.
4.5 The AC shall verify that the allocation of options pursuant to the Apex Healthcare Berhad Employee Share Option Scheme, where any such Scheme is in operation, is in compliance with criteria that have been disclosed to employees as required under the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.
4.6 The AC is assisted and supported by the Risk and Sustainability Committee to oversee the company’s risk management framework and policies. The head of Internal Audit reports directly to the AC. The head of Internal Audit should have the relevant qualifications and responsibilities for providing assurance to the AC that the internal controls are operating effectively. For administrative and operational matters, the Internal Auditors will liaise with either the Chief Executive Officer (“CEO”) or Financial Controller (“FC”).
4.7 The AC shall function as the Anti-Corruption Oversight Committee as well. Therefore, the head of Anti-Corruption Function of the Group reports directly to the AC. The head of Anti-Corruption Function is responsible for the anti-corruption compliances of the Group and for ensuring that the anti-corruption monitoring programme are being implemented on a timely basis. The Anti-Corruption Function is also responsible to assist the AC in any investigation and also to ensure that the Group’s anti-corruption policies and procedures are being complied with. For administrative and operational matters, the Anti-Corruption Function will liaise with either the Chief Executive Officer (“CEO”) or Financial Controller (“FC”) on a day to day basis.
4.8 The Chairman of the AC should engage on a continuous basis with Senior Management in order to be kept informed of matters affecting the Company or Group.
4.9 The AC shall conduct meetings independently and separately from time to time with Internal and External Auditors; and
4.10 The AC shall conduct any other duties as may be assigned by the Board of Directors from time to time.
5. Attendance at Meetings
5.1 The CEO, FC, the key representatives of the External and Internal Auditors shall normally attend meetings.
5.2 Other Board members and employees may also attend AC meetings only at the AC’s invitation, specific to the relevant meeting.
6. Procedure of Audit Committee
6.1 The AC shall regulate its own procedure, in particular:
- the calling of meetings;
- the notice to be given of such meetings;
- the voting and proceedings of such meetings;
- the keeping of minutes; and
- the custody, production and inspection of such minutes.
6.2 The AC shall meet at least 4 times a year. The AC shall meet with the External Auditors and Internal Auditors, without the presence of any employee, at least twice a year. The External Auditors may request a meeting if they consider that one is necessary.
6.3 The Secretary shall circulate the minutes of meetings of the AC to all members of the Board of Directors.
6.4 The AC shall prepare a report to the Board that provides details of the activities of the AC, number of AC meetings held in a year, details of attendance of Directors at such meetings and details of relevant training attended by each Director for inclusion in the Company’s Annual Report.
6.5 A resolution in writing signed by all of the members of the AC shall be as valid and effectual as if it had been passed at a meeting of the members duly convened and held. Any such resolution may consist of several documents in like form, each signed by one or more members. Any such documents may be accepted as sufficiently signed by a member if transmitted to the Company by telegram, telex, facsimile or other electrical written message purporting to include a signature of the member.
Appendix B
Terms of Reference of the Remuneration Committee
1. Constitution
The Board has established a Committee of the Board to be known as the Remuneration Committee (hereinafter referred to as the “RC”) with authority and duties as specified in these Terms of Reference.
2. Membership of the Committee
2.1 The RC shall be appointed by the Board from amongst themselves and shall comprise exclusively of Non-Executive Directors, the majority of whom shall be independent. The appointment of a Committee member terminates when the member ceases to be a Director, or as determined by the Board.
2.2 The members of the RC shall elect a Chairman from among their members.
2.3 The Company Secretary shall be the Secretary of the RC.
3. Meetings
3.1 The Committee shall meet at least once a year. More meetings may be conducted if the need arises. The quorum for a meeting of the RC shall be two (2) members.
3.2 A resolution in writing, signed by all the members of the Committee, shall be as valid and effectual as if it has been passed at a meeting of the members duly convened and held. Any such resolution may consist of several documents in like form, each signed by one or more members. Any such documents may be accepted as sufficiently signed by a member if transmitted to the Company by telegram, telex, facsimile or other electrical written message purporting to include a signature of the member.
3.3 The Company Secretary or his/her representative or other appropriate senior officer shall act as secretary of the Committee and shall be responsible in conjunction with the Chairman, for drawing up the agenda and circulating it, supported by explanatory documentation to Committee members prior to each meeting.
4. Guiding Principles
4.1 The levels of remuneration should be sufficient to attract and retain the Directors and Senior Management needed to run the company successfully. The component parts of remuneration should be structured so as to link rewards to corporate and individual performance, in the case of Executive Directors and Senior Management. In the case of Non-Executive Directors, the level of remuneration should reflect the experience and level of responsibilities undertaken by the particular non-executive concerned, taking into account any additional responsibilities undertaken such as chairmanship of a Board Committee or as the Senior Independent Director. The fees payable to Non-Executive Directors shall be by a fixed sum, and not by a commission on or percentage of profits or revenue.
There should be a formal and transparent procedure for developing remuneration policy on remuneration and for fixing the remuneration packages of individual Directors. The remuneration policy, which is applicable to Executive Director and Non-Executive Directors and Senior Management of the Group, is adopted by the Board based on the recommendations of the RC.
4.2 The Committee shall take into cognizance in its deliberations the Main Market Listing Requirements of Bursa Malaysia Securities Berhad and the principles in the Malaysia Code on Corporate Governance, and any other pertinent regulations and laws, as well as revisions which may come into force thereafter.
5. Duties and Functions of the Remuneration Committee
As provided in the remuneration policy, the RC is authorised by the Board to:
5.1 Review and determine, at least once annually, adjustments to the remuneration package, including benefits in kind, of each Executive Director and Senior Management of the Group, taking into account the corporate and individual performance, level of responsibility and complexity of the role, the inflation price index, and where necessary, information from independent sources on remuneration packages for equivalent jobs in the industry.
5.2 Review and determine the quantum of performance-related bonuses, benefits-in kind and Employee Share Options (or Executive Share Options), if available, to be given to the Executive Directors are linked to corporate and individual performance.
5.3 Review annually and recommend to the Board the level of fees paid to Non-Executive Directors, taking into consideration the fee levels and trends for similar positions in the market, time commitment required from the Director (estimated number of days per year). The review also takes into consideration any additional responsibilities undertaken by the Director acting as Chairman of a Board Committee or as Senior Independent Director.
5.4 Consider and execute the renewal of the service contracts of Senior Management of the Group, as and when due, as well as the service contracts and remuneration package for newly appointed Executive Director(s) prior to their appointment.
5.5 Execute any other duties as may be assigned by the Board of Directors from time to time.
Appendix C
Terms of Reference of the Nomination Committee
1. Constitution
The Board has established a Committee of the Board to be known as the Nomination Committee (hereinafter referred to as the “NC”) with authority and duties as specified in these Terms of Reference.
2. Membership of the Committee
2.1 The NC shall be appointed by the Board from amongst themselves, comprising exclusively of Non-Executive Directors, the majority of whom shall be independent. The appointment of a Committee member terminates when the member ceases to be a Director, or as determined by the Board.
2.2 The Chairman of the NC shall be a Senior Independent Non-Executive Director appointed by the Board. In the absence of the Chairman, the members present shall elect a Chairman from among themselves.
2.3 The Company Secretary shall be the Secretary of the NC.
3. Meetings
3.1 The Committee shall meet at least once a year. More meetings may be conducted if the need arises. The quorum for a meeting of the NC shall be two (2) members, a majority of whom must be Independent Directors.
3.2 A resolution in writing, signed by all the members of the Committee, shall be as effectual as if it has been passed at a meeting of the Committee duly convened and held. Any such resolution may consist of several documents in like form, each signed by one or more Committee members. Any such documents may be accepted as sufficiently signed by a member if transmitted to the Company by telegram, telex, facsimile or other electrical written message purporting to include a signature of the member.
3.3 The Company Secretary or his/her representative or other appropriate senior officer shall act as secretary of the Committee and shall be responsible in conjunction with the Chairman, for drawing up the agenda and circulating it, supported by explanatory documentation to Committee members prior to each meeting.
4. Principles
4.1 The ultimate decision on the appointment of Directors to the Board is the responsibility of the Board of Directors after due consideration of the recommendations of the NC.
4.2 The Board embraces diversity amongst its members and has ensured a good representation of the relevant skills and experience for the discharge of its duties. Its policy towards boardroom diversity is above all, to be non-discriminatory with regards to gender, race or religion, and only considering relevant qualifications, ability and commitment when proposing candidates for shareholders’ approval. This emphasis on diversity extends to the Senior Management.
4.3 The Board desires that each of its Directors, Chief Executive Officer, Chief Operating Officers and Financial Controller be of appropriate character, experience, integrity and competence so as to carry out their duties in the best interest of the Company. In addition, each of the Non-Executive Directors must be able to devote time to discharge their responsibilities in their respective roles and Board Committees.
4.4 The NC shall take into cognizance in its deliberations the Main Market Listing Requirements of Bursa Malaysia Securities Berhad and the principles of the Malaysia Code on Corporate Governance, and any other pertinent regulations and laws, as well as revisions which may come into force thereafter.
5. Duties and Functions of the Nomination Committee
The NC shall:
5.1 Assess and recommend to the Board, suitably qualified candidates for all directorships to be filled including new Directors and Directors to be re-elected or re-appointed or retained, taking into consideration candidates’
- skills, knowledge, expertise and experience;
- commitment (including time commitment) to effectively discharge his/her role as a Director;
- professionalism;
- gender, age and ethnicity and their pertinence to boardroom diversity;
- character, integrity and competence; and
- in the case of candidates for Independent Directors, ability to discharge the responsibilities and functions expected of Independent Non-Executive Directors.
The NC takes guidance from the Directors’ Fit and Proper Policy published on the Company’s website in its review and assessment of candidates that are to be appointed onto the Board of the Company and its subsidiaries as well as Directors who are seeking for re-election.
5.2 Seek, evaluate and recommend candidates for directorship as and when required. The NC should seek recommendations and referrals from shareholders, Directors, Senior Management and external independent sources where practicable in identifying appropriate candidates. Evaluation of candidates include the review of resumes, reference checks and interviews based on criteria established in the Directors’ Fit and Proper Policy for compliance with Para 2.20A of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. The NC will then recommend chosen candidates to the Board for consideration.
5.3 Assess annually the effectiveness of the Board as a whole, the Committees of the Board, individual Directors including Independent Non-Executive Directors, as well as the Chief Executive Officer and Chief Financial Officer through a process implemented by the Board. All assessments and evaluations carried out by the NC in the discharge of all its functions should be properly documented. The annual assessment takes the form of self-assessment questionnaires and the results are circulated and deliberated at meeting(s) of the NC and the outcome duly recorded in the minutes of the meeting(s) of the NC. The comments, recommendations and/or action plans for enhancements based on the evaluation results are tabled to the Board.
5.4 Assess the independence of the Independent Directors upon admission, annually and when any new interest or relationship develops and confirm the conduct of this assessment in the annual report of the Company and in any notice convening a general meeting seeking approval for the appointment and re-appointment of Independent Directors.
5.5 Recommend to the Board, Directors to fill the seats on other Board Committees.
5.6 Review annually the Board’s required mix of skills and experience and other qualities, including core competencies which Non-Executive Directors bring to the Board.
5.7 Determine appropriate training for Directors, review the fulfilment of such training, and disclose details in the annual report as appropriate, in accordance with Bursa Malaysia Securities Berhad’s guidelines on Directors’ Training.
5.8 Consider and recommend the Directors for re-election at each Annual General Meeting.
5.9 Consider and recommend the retention of each Independent Director who has served in that capacity for more than nine years at each Annual General Meeting.
5.10 Review the term of office and performance of the Audit Committee and each of its members annually to determine whether the Audit Committee and its members have carried out their duties in accordance with its Terms of Reference.
5.11 Consider the succession planning of members of the Board and Senior Management through a formalized Succession Planning policy to ensure sustainable and effective performance of the Board and Senior Management through planned succession and compliance with good governance practices.
5.12 Ensure that the composition of the Board is refreshed periodically.
5.13 Undertake any other duties as may be assigned by the Board of Directors from time to time.
Appendix D
Terms of Reference of the Risk and Sustainability Committee
1. Constitution
The Board has established a Committee of the Board to be known as the Risk and Sustainability Committee (hereinafter known as the “RSC” or “Committee”) with authority and duties as specified in these Terms of Reference.
2. Membership of the Commitee
2.1 The RSC shall be appointed by the Board from amongst themselves, comprising exclusively of Non-Executive Directors, the majority of whom shall be independent. The appointment of a Committee member terminates when the member ceases to be a Director, or as determined by the Board.
2.2 The Chairman of the RSC shall be an Independent Non-Executive Director appointed by the Board. In the absence of the Chairman, the members present shall elect a Chairman from among themselves.
2.3 The Company Secretary shall be the Secretary of the RSC.
2.4 A current member of the Audit Committee shall be a member of the RSC at any one time.
3. Meetings
3.1 The Committee shall meet at least once a year, or as often as required for the RSC to effectively discharge its role and responsibilities. The quorum for a meeting of the RSC shall be two (2) members.
3.2 A resolution in writing, signed by all the members of the Committee, shall be as valid and effectual as if it has been passed at a meeting of the members duly convened and held. Any such resolution may consist of several documents in like form, each signed by one or more members. Any such documents may be accepted as sufficiently signed by a member if transmitted to the Company by telegram, telex, facsimile or other electrical written message purporting to include a signature of the member.
3.3 The Company Secretary or his/her representative or other appropriate senior officer shall act as secretary of the Committee and shall be responsible in conjunction with the Chairman, for drawing up the agenda and circulating it, supported by explanatory documentation to Committee members prior to each meeting.
3.4 he Chairman of the Audit Committee shall be invited to all RSC meetings.
4. Principles
4.1 The RSC is mandated by the Board to oversee the Company’s Risk Management and Sustainability framework and policies and to be responsible for the Company’s overall implementation of sustainability strategies.
4.2 The Committee shall make recommendations to the Board it deems appropriate on any area within its remit where action or improvement is needed.
4.3 The Board as a whole is ultimately responsible for all the actions of the Committee with regard to the execution of the delegated role and this includes the outcome of the review and disclosure on key risks and internal control in the Statement on Risk Management and Internal Control and sustainability report in the Sustainability Statement of the Company’s Annual Report.
4.4 The RSC shall take into cognizance in its deliberations the Listing Requirements of Bursa Malaysia Securities Berhad and the principles of the Malaysia Code on Corporate Governance, and any other pertinent regulations and laws, as well as revisions which may come into force thereafter.
5. Duties and Functions of the Risk and Sustainability Committee
5.1 Risk Management
5.1.1 Ensure that the strategic context of the risk management strategy is aligned with the long-term business strategy taking into account the business environment within which the Company operates and the interests of its stakeholders.
5.1.2 Oversee, review and make recommendations to the Board regarding the Company’s risk management framework and assess its adequacy and effectiveness.
5.1.3 Profile the risks of the Company including analysing the Company’s business units and the various categories of risks faced by the Company and oversee management’s recommended action plans for managing risk.
5.1.4 Review with the internal auditors the Company’s annual Risk Assessment Report relating to material risks of the Company.
5.1.5 Review annually the adequacy of the Group’s insurance coverage.
5.1.6 Assess the structure and adequacy of the Company’s Business Continuity Plans.
5.1.7 Assist and support the Audit Committee in the preparation of the Statement on Risk Management and Internal Control for the Audit Committee’s recommendation to the Board for inclusion in the Company’s Annual Report.
5.1.8 Undertake any other duties as may be assigned by the Board of Directors from time to time in relation to risk management matters.
5.2 Sustainability
5.2.1 Ensure that the Group’s sustainability efforts are aligned with the long-term business strategy taking into account the business environment within which the Company operates and the interests of its stakeholders.
5.2.2 Oversee, review and make recommendations to the Board regarding the Company’s material economic, environmental and social matters impacting the principal businesses of the Company.
5.2.3 Annually review and present to the Board for approval of the Company’s Sustainability Statement for inclusion in the Company’s Annual Report.
5.2.4 Undertake any other duties as may be assigned by the Board of Directors from time to time in relation to sustainability matters.
Our Vision
Through manufacturing and distribution, Apex makes quality pharmaceutical and consumer healthcare products available to our valued customers through our comprehensive supply channels.
Since our establishment in 1962, our business has been focused on making pharmaceutical and consumer healthcare products available to customers in the markets in which we operate, through manufacturing and distribution, and in a manner which fairly rewards all stakeholders. We know our business intimately and have a growing network of loyal customers; this will remain our business for the future. Our confidence in our business stems from a conscious decision to focus resources on our area of expertise, which enables us to increase our capabilities, efficiencies and understanding of underlying trends in the industry.
Board of Directors
Non-Independent
Non-Executive Director
Company Secretaries
Chiew Woon Wui
SSM PC no. 201908001112 [MIA 20586]
Chan Yoke Peng
SSM PC no. 202008001791 [MAICSA 7053966]
Auditors
Ernst & Young PLT
Registration no. 202006000003 (LLP0022760-LCA) & AF 0039
Chartered Accountants
Level 23A Menara Milenium
Jalan Damanlela
Pusat Bandar Damansara
50490 Kuala Lumpur